Search hospitals > Massachusetts > Boston

Boston Children's Hospital

Claim this profile
Boston, Massachusetts 02115
Global Leader in Cystic Fibrosis
Global Leader in Congenital Heart Diseases
Conducts research for Sickle Cell Disease
Conducts research for Epilepsy
Conducts research for Congenital Heart Disease
1223 reported clinical trials
124 medical researchers
Photo of Boston Children's Hospital in BostonPhoto of Boston Children's Hospital in BostonPhoto of Boston Children's Hospital in Boston

Summary

Boston Children's Hospital is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cystic Fibrosis, Congenital Heart Diseases, Sickle Cell Disease, Epilepsy, Congenital Heart Disease and other specialties. Boston Children's Hospital is involved with conducting 1,223 clinical trials across 1,618 conditions. There are 124 research doctors associated with this hospital, such as Susan Chi, MD, Dr. David Brown, Katherine A. Janeway, and Steven G. DuBois, MD, MS.

Area of expertise

1Cystic Fibrosis
Global Leader
Boston Children's Hospital has run 99 trials for Cystic Fibrosis. Some of their research focus areas include:
CFTR
CFTR positive
CF-causing mutations positive
2Congenital Heart Diseases
Global Leader
Boston Children's Hospital has run 58 trials for Congenital Heart Diseases.

Top PIs

Clinical Trials running at Boston Children's Hospital

Crohn's Disease
Ulcerative Colitis
Colitis
Inflammatory Bowel Disease
Down Syndrome
Rett Syndrome
Pneumonia
Heart Failure
Postoperative Pain
Acute Lymphoblastic Leukemia
Image of trial facility.

Anti-TNF Therapy

for Crohn's Disease in Children

Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.
Recruiting3 awards Phase 47 criteria
Image of trial facility.

Vedolizumab

for Ulcerative Colitis and Crohn's Disease

The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Recruiting3 awards Phase 3
Image of trial facility.

Vedolizumab

for Crohn's Disease

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.
Recruiting2 awards Phase 36 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Boston Children's Hospital?
Where is Boston Children's Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Boston Children's Hospital accept?
What awards or recognition has Boston Children's Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security